## Italy’s Billionaire Angelini Family Makes a Splash in the U.S. Pharma Market

In an exciting twist for the world of pharmaceuticals, the Angelini family, a billionaire dynasty with roots stretching back over a century, has decided to pack their bags and make a bold leap into the U.S. market. Based in Italy, the Angelini family previously kept things local, focusing mainly on their European empire that spans pharmaceuticals, consumer goods, wineries, and even robotics. However, with the marriage of Sergio Marulo de Condojanni and Thea Paola Angelini in 2017, the family has set its sights on new horizons—one that includes the ever-elusive and lucrative pharmaceutical landscape of the United States.

Back when grandma and grandpa were building their Italian pharmaceutical legacy, no one could have predicted that their great-grandchild would be eyeing the various wonders of the U.S. market. Marulo de Condojanni, now the head honcho of Angelini Pharma, has expressed a strong conviction that if they want to make waves in the pharma space, entering the United States is essential. With a vibrant and innovative pharmaceutical market, it just makes good sense. After all, who wouldn’t want to swim in a pool with the big fish?

Last November, as the chill of fall crept over London, Marulo de Condojanni was busy at a fancy hotel, chatting it up with Rich Daly, the CEO of Catalyst Pharmaceuticals, a company with a keen focus on rare diseases. They hit it off over their mutual interests in drug development, finding common ground despite the ocean separating their headquarters. With the ink barely dry on their agreement, Angelini Pharma made their move in May, establishing a $4.1 billion deal that officially brought Catalyst under their umbrella in July. With this acquisition, the Italian firm not only gained entry into the U.S. market but also expanded their revenue base by an impressive 40%, right off the bat.

For Thea Paola Angelini, the family’s controlling shareholder and a formidable force in her own right, this is no simple shift. With a family fortune estimated at around $10 billion, positioning their business for growth is both a responsibility and an opportunity. Along with her teammates, she is determined to turn this sleepy legacy into a powerhouse once again. They are not merely satisfied with the cash flow from drugs created decades ago; they are hungry for innovation, eyeing the next big breakthrough.

While the U.S. market is often viewed like a fiery dragon to tame, Angelini Pharma is stepping onto the field with a game plan. Rare diseases may present unique challenges, but they lack the intense competition seen in broader markets like cancer drugs, where giants like Vertex Pharmaceuticals reign supreme. Angelini Pharma is hoping to use its purchase of Catalyst as a launchpad for future innovations and potentially become a known player in the U.S. pharmaceutical scene.

In what seems like a refreshing change of pace, this move also signals a shift in mindset among family-owned businesses in Italy. Historically, many companies have kept their operations firmly within Europe. However, with more ambitious entrepreneurs like Marulo de Condojanni and Thea Paola Angelini leading the charge, the culture is evolving. While venturing into the unknown can feel daunting, the rewards of entering the U.S. market could be well worth the effort.

So, as the Angelini family takes their first steps into this exciting chapter of their business journey, they may very well be writing a new playbook for family-run companies eager to expand beyond their borders. With audacious vision and the determination to remain relevant in today’s fast-paced market, it looks like the Angelini family is ready to pop some champagne and toast to new beginnings. Cheers to them!